Clinical trialObservationalCompleted
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- Observational
- Status
- Completed
- Study type
- Observational
- Start
- 10 August 2022
- Ended
- 30 August 2025
- Enrollment
- 19 participants
- Sites
- 1
- Primary outcomes
- Pain severity-BPI; Pain severity-VAS; Pain severity-NRS; Quality of Life (EORTC PAN26); Quality of Life (EORTC C30)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 28 April 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.